Latest Breaking News On - Sol katzman - Page 1 : comparemela.com

Tiny target discovered on RNA to short-circuit inflammation

Researchers have discovered a peptide in human RNA that regulates inflammation and may provide a new path for treating diseases such as arthritis and lupus. The team used a screening process based on the powerful gene-editing tool CRISPR to shed light on one of the biggest mysteries about our RNA the molecule responsible for carrying out genetic information contained in our DNA.

New study discovers tiny target on RNA to short-circuit inflammation

Eliminating RNA-binding protein improves survival in aggressive leukemia

Scientists find that removing IGF2BP3 selectively targets cancer cells while leaving healthy cells alone UCLA Broad Stem Cell Research Center Dr. Dinesh Rao and his colleagues had previously identified the IGF2BP3 protein as a factor in driving the development of leukemia through its regulation of RNA messages. Denise Heady | July 28, 2021 Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer’s development and significantly increase the likelihood of survival, according to a study in mice led by scientists at the UCLA Jonsson Comprehensive Cancer Center. The research, published today in the journal Leukemia, could aid in the development of targeted therapies for cancers that have high levels of the RNA-binding protein IGF2BP3 especially acute lymphoblastic and myeloid leukemias that are characterized by chromosomal rearrangements in the mixed lineage leukemia (MLL) gene.

Removing RNA-binding protein in subtype of leukemia can help to slow the cancer's development

Removing RNA-binding protein in subtype of leukemia can help to slow the cancer s development Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer s development and significantly increase the likelihood of survival, according to a study in mice led by scientists at the UCLA Jonsson Comprehensive Cancer Center. The research, published in the journal Leukemia, could aid in the development of targeted therapies for cancers that have high levels of the RNA-binding protein IGF2BP3 -; especially acute lymphoblastic and myeloid leukemias that are characterized by chromosomal rearrangements in the mixed lineage leukemia (MLL) gene.

Eliminating RNA-binding protein improves survival in aggressive leukemia